CA2383224A1 - Extracts of orange peel for prevention and treatment of cancer - Google Patents

Extracts of orange peel for prevention and treatment of cancer Download PDF

Info

Publication number
CA2383224A1
CA2383224A1 CA002383224A CA2383224A CA2383224A1 CA 2383224 A1 CA2383224 A1 CA 2383224A1 CA 002383224 A CA002383224 A CA 002383224A CA 2383224 A CA2383224 A CA 2383224A CA 2383224 A1 CA2383224 A1 CA 2383224A1
Authority
CA
Canada
Prior art keywords
extract
methoxyflavone
hydroxy
animal
resveratrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002383224A
Other languages
French (fr)
Other versions
CA2383224C (en
Inventor
Geetha Ghai
Robert T. Rosen
Chi-Tang Ho
Kuang Yu Chen
Nitin Telang
Martin Lipkin
Mou Tuan Huang
Charles Boyd
Katalin Csiszar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Geetha Ghai
Robert T. Rosen
Chi-Tang Ho
Kuang Yu Chen
Nitin Telang
Martin Lipkin
Mou Tuan Huang
Charles Boyd
Katalin Csiszar
Rutgers, The State University Of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geetha Ghai, Robert T. Rosen, Chi-Tang Ho, Kuang Yu Chen, Nitin Telang, Martin Lipkin, Mou Tuan Huang, Charles Boyd, Katalin Csiszar, Rutgers, The State University Of New Jersey filed Critical Geetha Ghai
Publication of CA2383224A1 publication Critical patent/CA2383224A1/en
Application granted granted Critical
Publication of CA2383224C publication Critical patent/CA2383224C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Compositions and methods of inhibiting tumor cell growth and treating and preventing cancer are provided based on administration of an orange peel extract either alone or in combination with other phytochemicals.

Claims (8)

1. An extract of orange peel comprising 4',5,6,7,8-pentamethoxyflavone and 3',4',5,6,7,8-hexamethoxyflavone.
2. The extract of claim 1 further comprising at least one compound selected from the group consisting of 5-hydroxy-6,7,8,3',4'-pentamethoxyflavone, 5-hydroxy-7,8,3',4'-methoxyflavone, 5,7-hydroxy-6,8,3',4'-methoxyflavone, 5,7,8,3',4'-pentamethoxyflavone, 5,7,8,4'-methoxyflavone,
3,5,6,7,8,3',4'-methoxyflavone, 5-hydroxy-3,6,7,8,3',4'-methoxyflavone, 5-hydroxy-6,7,8,4'-methoxyflavone, 5,6,7,4'-methoxyflavone, 7-hydroxy-3,5,6,8,3',4'-methoxyflavone, and 7-hydroxy-3,5,6,3',4'-methoxyflavone.

3. A composition comprising the extract of claim 1 and at least one other compound selected from the group consisting of rosemary extract, a Mexican Bamboo extract, a Huzhang extract, resveratrol, a black tea extract, and a hydroxylated or methoxylated resveratrol analog.
4. A composition comprising the extract of claim 2 and at least one other compound selected from the group consisting of rosemary extract, a Mexican Bamboo extract, a Huzhang extract, resveratrol, a black tea extract, and a hydroxylated or methoxylated resveratrol analog.
5. A method for inhibiting tumor cell growth in an animal comprising administering to an animal the extract of claim 1 or claim 2.
6. A method for inhibiting tumor cell growth in an animal comprising administering to an animal the composition of claim 3 or claim 4.
7. A method for preventing or treating cancer in an animal comprising administering to an animal an effective amount of an extract of claim 1 or claim 2.
8. The method of claim 7 further comprising administering at least one additional compound selected from the group consisting of a rosemary extract, a Mexican Bamboo extract, a Huzhang extract, resveratrol, a hydroxylated resveratrol analog, a black tea extract, and a methoxylated resveratrol analog.
CA2383224A 1999-09-21 2000-09-20 Extracts of orange peel for prevention and treatment of cancer Expired - Fee Related CA2383224C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15501899P 1999-09-21 1999-09-21
US60/155,018 1999-09-21
PCT/US2000/025733 WO2001021137A1 (en) 1999-09-21 2000-09-20 Extracts of orange peel for prevention and treatment of cancer

Publications (2)

Publication Number Publication Date
CA2383224A1 true CA2383224A1 (en) 2001-03-29
CA2383224C CA2383224C (en) 2010-12-07

Family

ID=22553801

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2383224A Expired - Fee Related CA2383224C (en) 1999-09-21 2000-09-20 Extracts of orange peel for prevention and treatment of cancer

Country Status (5)

Country Link
EP (1) EP1214040A4 (en)
JP (1) JP2003509447A (en)
AU (1) AU7384900A (en)
CA (1) CA2383224C (en)
WO (1) WO2001021137A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100833805B1 (en) * 2000-04-19 2008-05-30 니치유 가부시키가이샤 Cosmetic composition
WO2002039956A2 (en) 2000-11-15 2002-05-23 Rutgers, The State University Of New Jersey Black tea extract for prevention of disease
US7087790B2 (en) 2003-08-29 2006-08-08 Rutgers, The State University Of New Jersey Benzotropolone derivatives and modulation of inflammatory response
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US20070042972A1 (en) * 2005-05-24 2007-02-22 Mckeever Kenneth H Compositions and methods for optimizing exercise recovery
WO2007135569A2 (en) * 2006-02-09 2007-11-29 Kgk Synergize Inc Methods of treating canine osteosarcoma
WO2008035208A2 (en) * 2006-05-19 2008-03-27 Kgk Synergize Inc The use of flavonoids for the inhibition of cellular growth
CN100422168C (en) * 2006-06-15 2008-10-01 中国科学技术大学 Hesperetin derivant and preparation process thereof
DE102007037772A1 (en) * 2007-08-10 2009-02-12 Csabai, Zsolt, Dr. Ph. Antioxidant complex based on Grape Vital (citrus and / or grape seed and / or flavonoid base)
JP5742050B2 (en) * 2011-03-01 2015-07-01 国立研究開発法人農業・食品産業技術総合研究機構 NK cell activator and NK cell activation method
WO2013172682A1 (en) 2012-05-16 2013-11-21 연세대학교 산학협력단 Use of flavone compound for prevention or treatment of obesity
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
SG11201804473RA (en) * 2015-12-07 2018-06-28 Univ Kyoto Pd-1 signal inhibitor combination therapy
CN115772145A (en) * 2022-11-29 2023-03-10 三峡大学 Citrus fruit extract and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0824320A4 (en) * 1995-05-05 2000-06-07 Hauser Inc High purity carnosic acid from rosemary and sage extracts by ph-controlled precipitation
JPH09176009A (en) * 1995-12-27 1997-07-08 Inahata Koryo Kk New antimutagenic agent and substance having antimutagenic action
US5830738A (en) * 1996-06-04 1998-11-03 Clemson University Extraction of pigment from plant material
US6251400B1 (en) * 1997-09-26 2001-06-26 Kgk Synergize Inc Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols
JP3571899B2 (en) * 1997-12-18 2004-09-29 小川香料株式会社 Flavor deterioration inhibitor

Also Published As

Publication number Publication date
JP2003509447A (en) 2003-03-11
WO2001021137A1 (en) 2001-03-29
EP1214040A4 (en) 2004-06-23
CA2383224C (en) 2010-12-07
WO2001021137A8 (en) 2001-07-26
AU7384900A (en) 2001-04-24
EP1214040A1 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
CA2383224A1 (en) Extracts of orange peel for prevention and treatment of cancer
CA2431196A1 (en) Black tea extract for prevention of disease
WO2001080843A3 (en) Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
IL145492A0 (en) Methods and compositions for treating solid tumors
AP1666A (en) Quinolinone derivatives as tyrosine kinase inhibitors.
YU75003A (en) A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
AU4451101A (en) Method and compositions for preventing hormone induced adverse effects
CA2326761A1 (en) Antitumor agent
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
GEP20043322B (en) C7 Ester Substituted Taxanes as Antitumor Agents, Pharmaceutical Compositions Containing the Same and Use Thereof for Inhibiting Tumors
CA2418479A1 (en) Prodrugs of betulinic acid derivatives for the treatment of cancer
WO2007147128A3 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
KR100352030B1 (en) Gum composition for removing nicotine
AU4830097A (en) Use of an extract of Cimicifuga
MX9800945A (en) Use of griseofulvin for inhibiting the growth of cancers.
EP0819433A3 (en) Compositions for increasing the efficacy of cancer drugs with tea catechin and/or theaflavin
AU2162202A (en) Antitumor therapy comprising distamycin derivatives
WO2002062952A3 (en) Non-cytotoxic pap mutants
NZ523606A (en) Pharmaceutical compositions and methods for use
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
IL131096A0 (en) Muscle-derived compositions
WO2001082908A3 (en) Ginsenoside chemotherapy
WO2000059488A3 (en) Enhanced tissue and subcellular delivery of vitamin e compounds

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140922